Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Morphic Holding Inc (NQ: MORF ) 56.99 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Morphic Holding Inc < Previous 1 2 3 Next > Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors November 22, 2023 From Robbins LLP Via Business Wire Morphic to Present at November Investor Conferences November 10, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023 November 03, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 7/17 July 17, 2023 Via Investor Brand Network Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 6/5 June 05, 2023 Via Investor Brand Network Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 5/10 May 10, 2023 Via Investor Brand Network NASDAQ: MORF Investor Notice: Investigation over Possible Securities Laws Violations by Morphic Holding, Inc. November 01, 2023 San Diego, CA -- (SBWIRE) -- 11/01/2023 -- Morphic Holding, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation October 21, 2023 From Johnson Fistel, LLP Via Business Wire Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation October 14, 2023 From Johnson Fistel, LLP Via Business Wire Morphic Holding Inc. (NASDAQ: MORF) Highlighted for Surprising Price Action April 17, 2023 Via Investor Brand Network Morphic Holding Inc. (NASDAQ: MORF) Leading the Way in Monday Trading Based on Percentage Gain April 17, 2023 Via Investor Brand Network Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set October 09, 2023 From Morphic Therapeutic Via GlobeNewswire MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm September 29, 2023 From Robbins Geller Rudman & Dowd LLP Via Business Wire Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence September 26, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023 September 22, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference August 29, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference August 09, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023 August 03, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic to Present at the Jefferies Global Healthcare Conference June 06, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference May 12, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis May 11, 2023 -Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition- From Morphic Therapeutic Via GlobeNewswire Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares May 05, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering May 03, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Therapeutic Announces Proposed Public Offering May 02, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures April 25, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023 April 25, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023 April 24, 2023 Call to discuss topline data from EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis From Morphic Therapeutic Via GlobeNewswire Morphic to Present at TD Cowen 43rd Annual Health Care Conference March 03, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022 February 23, 2023 From Morphic Therapeutic Via GlobeNewswire Morphic to Present at SVB Leerink Global Healthcare Conference February 14, 2023 From Morphic Therapeutic Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.